Provided by

Enquire about this course

About the course

Grapiprant (brand name Galliprant) is a new class of drug licensed in Europe (via the European Medicines Agency [EMA]) for treating ‘pain associated with mild to moderate osteoarthritis in dogs’ . There are concerns among dog owners and vets about the safety of NSAIDs, which is in contrast to the evidence on NSAIDs, but which has led to reluctance to use them. So, there is a lot of interest in grapiprant from dog owners and vets because they hope it is an effective and safer alternative to traditional NSAIDs. By doing this module you will:

  • understand the pharmacology of grapiprant;

  • know the clinical evidence on the efficacy and safety of grapiprant;

  • be aware of what is known about how grapiprant compares with NSAIDs;

  • understand what is meant by intention-to-treat and per-protocol analysis in clinical trials result analysis;

  • understand what is meant by the number needed to treat and its relevance to clinical practice.


Start date Location / delivery
No fixed date Online

Related article

Adam Bernstein explains why CPD is so important and explores the various ways vets and vet nurses can maintain and develop their knowledge and skills.